secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2026-05-14T11:12:20+00:00
Accession:  0001193125-26-222762
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd Q1 net product revenue $13.7M (+22% YoY); net loss $41.4M; VYD2311 data delayed to Q3 2026
--------------------------------------------------------------------------------

- Q1 2026 PEMGARDA net product revenue $13.7M, up 22% YoY vs $11.3M.
- Net loss $41.4M ($0.13/sh) vs $16.3M ($0.14/sh) in Q1 2025; R&D expense rose to $30.7M.
- Cash $184.2M at Mar 31; raised ~$20M via ATM in Apr 2026, extending runway through VYD2311 launch.
- DECLARATION trial upsized by ~500 subjects; top-line data now expected in Q3 2026 (shift from mid-year).
- IDMC reduced VYD2311 post-dose monitoring from 2 hours to 30 min; in vitro neutralization vs BA.3.2.2 confirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/0001193125-26-222762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/d120795d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-222762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer